CA3152485A1 - Azepane derivative - Google Patents

Azepane derivative Download PDF

Info

Publication number
CA3152485A1
CA3152485A1 CA3152485A CA3152485A CA3152485A1 CA 3152485 A1 CA3152485 A1 CA 3152485A1 CA 3152485 A CA3152485 A CA 3152485A CA 3152485 A CA3152485 A CA 3152485A CA 3152485 A1 CA3152485 A1 CA 3152485A1
Authority
CA
Canada
Prior art keywords
group
substituent
optionally
group optionally
ddd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3152485A
Other languages
English (en)
French (fr)
Inventor
Yoshikazu Watanabe
Daisuke Saito
Kohei HAYASHIDA
Kohei Yamamoto
Mayu NAMIKI
Yuzo MOGI
Masahiro Yata
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Chemiphar Co Ltd
Original Assignee
Nippon Chemiphar Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co Ltd filed Critical Nippon Chemiphar Co Ltd
Publication of CA3152485A1 publication Critical patent/CA3152485A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/0803—Compounds with Si-C or Si-Si linkages
    • C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
    • C07F7/0816—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring said ring comprising Si as a ring atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02—Silicon compounds
    • C07F7/08—Compounds having one or more C—Si linkages
    • C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804—Compounds having Si-O-C linkages
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3152485A 2019-09-30 2020-09-29 Azepane derivative Pending CA3152485A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2019179727 2019-09-30
JP2019-179727 2019-09-30
PCT/JP2020/036868 WO2021065898A1 (ja) 2019-09-30 2020-09-29 アゼパン誘導体

Publications (1)

Publication Number Publication Date
CA3152485A1 true CA3152485A1 (en) 2021-04-08

Family

ID=75338310

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3152485A Pending CA3152485A1 (en) 2019-09-30 2020-09-29 Azepane derivative

Country Status (8)

Country Link
US (1) US20230087342A1 (https=)
EP (1) EP4039331A4 (https=)
JP (1) JP7678756B2 (https=)
KR (1) KR20220071223A (https=)
CN (1) CN114761082A (https=)
AU (1) AU2020360928A1 (https=)
CA (1) CA3152485A1 (https=)
WO (1) WO2021065898A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022210479A1 (ja) * 2021-03-29 2022-10-06 日本ケミファ株式会社 アゼパン誘導体のκオピオイド受容体関連疾患の治療、改善又は予防のための使用

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US963460A (en) 1910-02-23 1910-07-05 Peter N Moore Roller side bearing.
JP2525552Y2 (ja) 1990-10-26 1997-02-12 株式会社間組 シャワールームユニット
GB9118597D0 (en) 1991-08-30 1991-10-16 Biocompatibles Ltd Polymer treatments
ES2121988T3 (es) 1992-01-23 1998-12-16 Toray Industries Derivado de morfinano y uso medicinal.
CA2296329A1 (en) 1997-07-24 1999-02-04 Masakazu Nakano Aminocycloalkane compounds
BRPI0719937A2 (pt) 2006-12-05 2014-03-11 Neurogesx Inc Pró-fármacos e métodos de fazer e de usar os mesmos
JP2008179554A (ja) 2007-01-24 2008-08-07 Toray Ind Inc ピロール縮合モルヒナン誘導体およびその医薬用途
MX2009012610A (es) * 2007-05-22 2009-12-11 Astellas Pharma Inc Compuesto de tetrahidroisoquinolina 1-sustituido.
WO2010021149A1 (ja) 2008-08-21 2010-02-25 武田薬品工業株式会社 酸分泌抑制スピロ化合物
MX2011009571A (es) 2009-03-13 2011-10-19 Boehringer Ingelheim Int Inhibidores de beta-secretasa.
EP2311823A1 (en) 2009-10-15 2011-04-20 AC Immune S.A. 2,6-Diaminopyridine compounds for treating diseases associated with amyloid proteins or for treating ocular diseases
US20130144053A1 (en) 2011-12-05 2013-06-06 Mallinckrodt Llc Process for the Production of Seven-Membered Lactam Morphinans
MA40171A (fr) * 2014-06-13 2017-04-19 Purdue Pharma Lp Dérivés d'azamophinan et leur utilisation
CA2960280A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Substituted piperidine compounds
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
WO2018125716A1 (en) * 2017-01-02 2018-07-05 Purdue Pharma L.P. Morphinan derivatives and use thereof
KR20190117582A (ko) 2017-02-10 2019-10-16 쥐원 쎄라퓨틱스, 인크. 벤조티오펜 에스트로겐 수용체 조정제
CA3055194A1 (en) 2017-03-02 2018-09-07 Assembly Biosciences, Inc. Cyclic sulfamide compounds and methods of using same
JPWO2019045006A1 (ja) * 2017-08-31 2020-10-01 国立大学法人 筑波大学 モルヒナン誘導体
JP7348714B2 (ja) 2018-03-30 2023-09-21 古河電気工業株式会社 カーボンナノチューブ線材、カーボンナノチューブ被覆電線、カーボンナノチューブ線材の製造方法及びカーボンナノチューブ被覆電線の加工方法
JP2022017604A (ja) 2018-10-22 2022-01-26 日本ケミファ株式会社 モルヒナン誘導体

Also Published As

Publication number Publication date
CN114761082A (zh) 2022-07-15
WO2021065898A1 (ja) 2021-04-08
EP4039331A4 (en) 2024-01-17
KR20220071223A (ko) 2022-05-31
JP7678756B2 (ja) 2025-05-16
JPWO2021065898A1 (https=) 2021-04-08
US20230087342A1 (en) 2023-03-23
AU2020360928A1 (en) 2022-04-14
EP4039331A1 (en) 2022-08-10

Similar Documents

Publication Publication Date Title
AU2019249849B2 (en) BRM targeting compounds and associated methods of use
CA3124898C (en) Heterocyclic compound, intermediate, preparation method therefor and application thereof
US12421249B2 (en) Inhibitors of APOL1 and methods of using same
US12162872B2 (en) Cycloalkylurea derivative
RU2679914C1 (ru) Конденсированные трициклические производные имидазола в качестве модуляторов активности tnf
JP2026509484A (ja) Ｋｒａｓモジュレーターおよびその使用
US11352357B2 (en) Cycloalkylurea derivative
JP7792964B2 (ja) オキサゼピン誘導体
CA3226724A1 (en) Cyanopyridine and cyanopyrimidine bcl6 degraders
TW202444350A (zh) 作為ｇｌｐ—１ｒ激動劑之化合物
TW202515851A (zh) Keap1抑制劑及其用途
TW202448866A (zh) 治療性化合物
WO2020085234A1 (ja) モルヒナン誘導体
CA3152485A1 (en) Azepane derivative
WO2019045006A1 (ja) モルヒナン誘導体
WO2021132524A1 (ja) エポキシアゼパン誘導体
KR20250073137A (ko) Egfr 억제제 및 그의 용도
WO2022210479A1 (ja) アゼパン誘導体のκオピオイド受容体関連疾患の治療、改善又は予防のための使用
WO2024204554A1 (ja) スピロ環状モルヒナン誘導体
HK40071875A (en) Azepan derivative
CN107922426B (zh) 四氢噁庚英吡啶化合物
TW202604484A (zh) 經取代之芳基磺醯胺及其組合物及用途
TW202542125A (zh) 烯烴類化合物、其製備方法及其在醫藥上的應用
TW202527922A (zh) 作為鈉通道抑制劑的雜芳基酯衍生物
HK40111671A (zh) 铁死亡调节剂、其制备和用途

Legal Events

Date Code Title Description
W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250825

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20251027

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251113

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20251231

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20260202

U13 Renewal or maintenance fee not paid

Free format text: ST27 STATUS EVENT CODE: N-1-6-U10-U13-U300 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: DEEMED ABANDONED - FAILURE TO RESPOND TO MAINTENANCE FEE NOTICE

Effective date: 20260330